Sonic Healthcare (SAB0) Price & Analysis
SAB0 Stock Chart & Stats
- Day’s Range
- EUR 11.70 - EUR 11.80
- 52-Week Range
- EUR 10.90 - EUR 14.10
- Previous Close
- EUR 11.60
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 6.07B
- Enterprise Value
- EUR 10.83B
- Total Cash (Recent Filing)
- EUR 653.73M
- Total Debt (Recent Filing)
- EUR 5.84B
- Price to Earnings (P/E)
- 15.9
- Beta
- 0.25
- Next Earnings
- Feb 22, 2027
- EPS Estimate
- 0.34
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 5.48%
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Profit Growth
Broad-based revenue, EBITDA and profit growth indicates that Sonic is expanding its diagnostic platform while converting demand into earnings. Continued scale across pathology and imaging can support reinvestment, strengthen customer reach, and provide a durable base for growth over the next several quarters.
Advanced Diagnostics Momentum
Strong growth in advanced diagnostics and direct-to-consumer testing supports a favorable service mix and demonstrates demand beyond routine laboratory work. These capabilities can deepen clinical relevance, improve differentiation, and create longer-term opportunities for higher-value diagnostic services.
M&A Synergies And Operating Improvement
Early synergy capture from the LADR acquisition and tangible U.S. cost actions show that management is integrating assets and improving the operating base. Realized efficiencies can support margins, increase returns on acquired businesses, and create internal funding for continued network development.
Bears Say
Swiss Regulatory Fee Reduction
The Swiss fee change is a structural reimbursement headwind rather than a temporary fluctuation, directly reducing revenue and putting pressure on margins. Sonic may offset part of the impact through synergies, but the regulatory reset lowers earnings quality and limits near-term growth in that market.
Weak Cash Conversion
Positive cash generation is tempered by inconsistent conversion of accounting profit into operating and free cash flow. This can reduce flexibility to fund acquisitions, technology investment and dividends internally, while making reported earnings less dependable as a measure of sustainable financial capacity.
Higher Leverage And Lower Returns
Rising leverage and weaker returns on equity indicate that Sonic is using more debt while generating less return from its capital base. Although equity remains substantial, higher funding reliance can constrain capital allocation and increase sensitivity to interest costs as the company invests and integrates acquisitions.
Sonic Healthcare News
SAB0 FAQ
What was Sonic Healthcare’s price range in the past 12 months?
What is Sonic Healthcare’s market cap?
When is Sonic Healthcare’s upcoming earnings report date?
How were Sonic Healthcare’s earnings last quarter?
Is Sonic Healthcare overvalued?
Does Sonic Healthcare pay dividends?
What is Sonic Healthcare’s EPS estimate?
How many shares outstanding does Sonic Healthcare have?
What happened to Sonic Healthcare’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sonic Healthcare?
What is the TipRanks Smart Score and how is it calculated?
Sonic Healthcare Stock Smart Score
Company Description
Sonic Healthcare
Headquartered in Sydney, Australia, Sonic Healthcare Limited, established in 1934, is a global provider of medical diagnostic and healthcare services. The company delivers a comprehensive range of laboratory medicine (pathology) services, alongside extensive diagnostic imaging and radiology capabilities, which include MRI, CT scans, ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. Beyond diagnostics, Sonic Healthcare also offers various primary care medical solutions. These encompass general practitioner services, occupational health support, remote healthcare provisions, community and in-home nursing, primary care research initiatives, health assessment technologies, clinical trial management, and chronic disease management programs. These crucial services are extended to medical professionals, hospitals, community health organizations, and their respective patients. Furthermore, the company provides administrative support and facilities to medical practitioners. Sonic Healthcare maintains a significant international presence, operating across Australia, New Zealand, the United Kingdom, the United States, Germany, Switzerland, Belgium, and Ireland.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James Pacey Newcombe
- Employees
- 49,000
- Website
- www.sonichealthcare.com
- Address
- Grosvenor Place, Sydney, NSW, 2000, AU
Sonic Healthcare (SAB0) Earnings & Revenues
SAB0 Company Deck
SAB0 Earnings Call
Earnings Call SentimentPositive
The call conveyed a predominantly positive performance picture: strong revenue, EBITDA and NPAT growth, solid organic expansion, and notable success in advanced diagnostics and M&A integration (notably Germany and Switzerland). Management also outlined proactive investments in digital transformation and clear U.S. turnaround actions expected to deliver AUD 25–30 million in FY2027 earnings. However, several near-term headwinds were emphasized, including regulatory fee cuts in Switzerland (CHF 20m), U.K. contract integration delays, software impairments and legacy IT write-downs, higher interest and capex in FY2026, FX and policy uncertainties (PAMA, GOÄ). On balance the highlights (growth, synergy capture, digital investment and disciplined capital management) outweigh the lowlights, although they limit near-term upside and keep guidance conservative.
View all DE:SAB0 earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 1 | 10 |
| Technical Analysis | 4 | 1 | 5 |
| Moving Averages | 7 | 0 | 5 |